Avoro Capital Advisors 13F: Exits MRUS Stake
Avoro Capital Advisors no longer holds any shares of MRUS after selling its entire position.
Reviewed by automated data checks against the source filing. How we make and check alerts
Avoro Capital Advisors sold its entire stake of 3,542,500 shares in Mrus ($MRUS), according to a 13F filing with the SEC dated February 17, 2026.
Find the original: Avoro Capital Advisors 13F filings on SEC EDGAR
Key Points
- Avoro Capital Advisors sold its entire stake of 3,542,500 shares in MRUS, as reported in its latest 13F filing.
- Several other institutional investors, including Eversource Wealth Advisors and XTX Topco Ltd, also completely exited their MRUS positions.
- Multiple analysts, including Leerink Partners and Guggenheim, downgraded MRUS to a hold rating in late 2025.
Get $MRUS trade alerts by text
We text you when insiders, Congress or big funds trade $MRUS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Mrus alert may contain errors. Disclosures
Avoro Capital Advisors has completely sold out of its position in MRUS, as shown in its recent filing with the SEC on February 17, 2026. The fund offloaded all 3,542,500 shares it previously held, marking a 100% reduction in its stake.
What Changed in Avoro Capital Advisors' MRUS Position
Avoro Capital Advisors reduced its holdings in MRUS by 3,542,500 shares, leaving it with no shares as of the filing. This move represents a complete exit from its prior position. Previously, the firm held 3,542,500 shares, indicating a full divestment.
Other Institutional Activity in MRUS
Several other institutional investors also sold out their positions in MRUS. Eversource Wealth Advisors, LLC reduced its holdings by 53 shares, ending with none. XTX Topco Ltd divested 26,768 shares, also exiting completely. Similarly, IFP Advisors, Inc, Farther Finance Advisors, LLC, NTV Asset Management LLC, and Brooklyn Investment Group each sold all their shares in MRUS, with reductions ranging from 3 to 2,452 shares.
Insider Buying and Selling at Mrus
Genmab A/S made significant insider purchases of MRUS shares in late December 2025. On December 29, Genmab A/S bought 76,920,005 shares at an average price of $97 per share. Earlier, on December 26, the company also acquired 2,978 shares and 142,610 shares, respectively, at the same price.
Analysts Set New Price Targets
In late 2025, several analysts downgraded MRUS to a hold rating. On October 6, 2025, Leerink Partners downgraded the stock, setting a price target of $97. Similarly, on September 30, Guggenheim, Canaccord Genuity, UBS, LifeSci Capital, Barclays, and HC Wainwright & Co. all issued hold ratings with the same target price. Truist Securities also downgraded the stock to hold on September 29.
Bottom Line
Avoro Capital Advisors' decision to sell all its MRUS shares is part of a broader trend among institutional investors, many of whom also exited their positions. The recent analyst downgrades to hold ratings reflect cautious sentiment around the stock. Investors will keep an eye on MRUS for any future developments, remembering that 13F filings are backward-looking and may not reflect current positions.
Source: Avoro Capital Advisors's 13F filing on $MRUS (Feb 17, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Avoro Capital Advisors 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts
